EXPERT EXCHANGE: Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors

Immune checkpoint inhibition (ICI) targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 pathway (PD-1/PD-L1) has dramatically improved the care of patients with many advanced malignancies.1...

 Read More

EXPERT EXCHANGE: Management of Advanced EGFR Mutation-Positive NSCLC: Making Bold Strides Toward True Precision Medicine

The discovery of epidermal growth factor receptor gene (EGFR) mutations in non–small cell lung cancer (NSCLC) and the development of EGFR tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment landscape of EGFR...

 Read More

CEC oncology is live. Visit our new site today.

 Read More